ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Exclusion Criteria

• •1. Patients with hepatocellular carcinoma who are candidates for surgical radical cure, or have undergone radical surgery without evaluable lesions, or have a history of or are planned for liver transplantation.
• •2. Pregnant or breastfeeding women.
• •3. Individuals with known allergy or intolerance to recombinant humanized PD-1/PD-L1 monoclonal antibody preparations.
• •4. Received local-regional therapy within 4 weeks before the first dose of the study drug, including but not limited to surgery, radiotherapy, hepatic artery embolism, TACE, hepatic artery infusion, radiofrequency ablation, cryoablation, or percutaneous ethanol injection.
• •5. History of other malignant tumors within 5 years prior to screening, except for hepatocellular carcinoma.
• •6. Presence of unhealed severe wounds, active ulcers, or untreated fractures.
• •7. Active autoimmune disease or history of autoimmune disorders.
• •8. Significant history of gastrointestinal diseases.
• •9. Significant history of cardiovascular or cerebrovascular diseases.